Background: Posaconazole tablets are well tolerated and efficacious in the prophylaxis and treatment of aspergillosis, mucormycosis, and other invasive fungal infections. There have been case reports of posaconazole-induced pseudohyperaldosteronism (PIPH); however, its occurrence and association with serum posaconazole drug levels have not previously been investigated.
Methods: In this single-center, retrospective, observational study, we examined the occurrence of PIPH in outpatients newly starting posaconazole and evaluated differences in serum posaconazole concentrations and clinical characteristics between those with and without this syndrome.
Results: Sixty-nine patients receiving posaconazole were included, of whom 16 (23.2%) met the definition of PIPH. Patients with PIPH were significantly older (61.1 vs 44.7 years, P = .007) and more frequently had hypertension prior to starting posaconazole (68.8% vs 32.1%, P = .009). Patients with PIPH had a significantly higher median serum posaconazole level than those without PIPH (3.0 vs 1.2 µg/mL, P ≤ .0001). There was a positive correlation between serum posaconazole levels and changes in systolic blood pressure (r = .37, P = .01), a negative correlation between serum posaconazole levels and changes in serum potassium (r = -.39, P = .006), and a positive correlation between serum posaconazole levels and serum 11-deoxycortisol (r = .69, P < .0001).
Conclusions: Posaconazole is associated with secondary hypertension and hypokalemia, consistent with pseudohyperaldosteronism, and development is associated with higher serum posaconazole concentrations, older age, and baseline hypertension.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286374 | PMC |
| http://dx.doi.org/10.1093/cid/ciz741 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparing the frequency, antifungal susceptibility, and enzymatic profiles of the oral fungal composition in patients with and without Alzheimer's disease admitted to a neurology clinic.
Front Cell Infect Microbiol
November 2024
Student research committee, Anzali International Medical Campus, Guilan University of Medical Sciences, Guilan, Iran.
Background: Studies have shown that changes in the frequency of oral microorganisms may play a key role in the development of Alzheimer's disease (AD). However, no research has been conducted on the oral fungal composition in AD-patients. The present study aimed to investigate the changes in the frequency of oral fungal composition, the antifungal susceptibility, and the enzymatic profiles of oral fungal composition in patients suffering from AD compared to non-AD individuals.
View Article and Find Full Text PDFEpidemiology, pathogenesis, clinical characteristics, and treatment of mucormycosis: a review.
Ann Med
December 2024
Center of Infectious Disease, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Article Synopsis
- This review summarizes key aspects of mucormycosis, including its epidemiology, causes, development, symptoms, and current diagnostic and treatment methods, aiming to enhance understanding for better outcomes.
- Mucormycosis is becoming more common due to factors like an increase in immunocompromised individuals, the COVID-19 pandemic, and improved detection techniques, but diagnosis is often delayed due to vague symptoms.
- Understanding the disease better and adopting effective diagnostic and treatment strategies are crucial for lowering mortality rates, making early detection and intervention vital for improved patient care.
Disseminated infection that could have been predicted: A case report.
IDCases
July 2024
Division of Clinical Research, Medical Mycology Research Center, Chiba University, Japan.
is a rare, filamentous fungus, that causes a disseminated infection in immunocompromised individuals. Disseminated infections caused by the fungus are difficult to diagnose early. It is resistant to multiple antifungal agents and has a high mortality rate.
View Article and Find Full Text PDFTherapeutic drug monitoring of mycophenolic acid and azole antifungals on two distinct LC-MS/MS instruments.
J Mass Spectrom Adv Clin Lab
August 2024
University of Wisconsin Hospital and Clinics, Madison, WI, United States of America.
Article Synopsis
- A multiplex LC-MS/MS assay has been developed to simultaneously measure mycophenolic acid (MPA) and several triazole antifungal drugs in serum, which is crucial for monitoring treatment in immunocompromised patients.
- The method involves a five-minute chromatographic separation and has shown excellent precision and a wide dynamic range for all measured drugs, with low limits of detection and quantitation.
- Validation results indicate that the assay performs well on different HPLC systems, demonstrating reliability and consistency for clinical applications.
Evaluation of Posaconazole Serum Concentrations Achieved With Delayed-release Tablets and Oral Suspension in Patients Undergoing Intensive Chemotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Open Forum Infect Dis
May 2024
Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Data on posaconazole serum levels of patients on prophylaxis with delayed-release tablets or oral suspension during intensive chemotherapy for acute myeloid leukemia and myelodysplastic syndrome are scarce. In this analysis, the proportion of patients with acute myeloid leukemia/myelodysplastic syndrome achieving posaconazole target concentrations with delayed-release tablets was higher than with oral suspension.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!